13G Filing: 683 Capital Partners and Tracon Pharmaceuticals Inc. (TCON)

Page 1 of 9

Tracon Pharmaceuticals Inc. (NASDAQ:TCON): Ari Zweiman’s 683 Capital Partners filed an amended 13D.

You can check out 683 Capital Partners’ latest holdings and filings here.

Please follow 683 Capital Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about 683 Capital Partners or update its stock holdings.

Follow Ari Zweiman's 683 Capital Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
683 Capital Management 0 895,000 0 895,000 895,000 5.4%
683 Capital Partners 0 895,000 0 895,000 895,000 5.4%
Ari Zweiman 0 895,000 0 895,000 895,000 5.4%

Follow Ari Zweiman's 683 Capital Partners

Page 1 of 9 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
SCHEDULE 13G
(RULE 13d – 102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
(Amendment No.)*
Tracon Pharmaceuticals, Inc.
(Name of Issuer)
Common stock, $0.001 par value
(Title of Class of Securities)
89237H100
(CUSIP Number)
September 18, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Tracon Pharmaceuticals Inc. (NASDAQ:TCON)

Page 1 of 9